التفاصيل البيبلوغرافية
| العنوان: |
Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment. |
| المؤلفون: |
Gerdes, Sascha, Staubach, Petra, Dirschka, Thomas, Wetzel, Dieter, Weirich, Oliver, Niesmann, Johannes, Mota, Rodrigo da, Rothhaar, Alex, Ardabili, Michael, Vlasitz, Gerda, Feldwisch, Joachim, Koskinen, Lisa Osterling, Ohlman, Sven, Peloso, Paul M, Brun, Nikolai C, Frejd, Fredrik Y |
| المصدر: |
British Journal of Dermatology; Oct2023, Vol. 189 Issue 4, p381-391, 11p |
| مصطلحات موضوعية: |
PSORIASIS, MOLECULAR size, TREATMENT effectiveness, MONOCLONAL antibodies, PATIENT safety |
| مستخلص: |
Background Monoclonal antibodies to interleukin (IL)-17 have shown strong efficacy in patients with psoriasis. Izokibep is a unique IL-17A inhibitor with a small molecular size and favourable distribution to sites of inflammation. Objectives To evaluate the dose response, efficacy and safety of izokibep in patients with plaque psoriasis. Methods In this double-blind, randomized, phase II dose-finding study (AFFIRM-35) in adults with moderate-to-severe plaque psoriasis and inadequate response to two or more standard therapies, patients were randomized (1:1:1:1:1) to placebo or izokibep 2, 20, 80 or 160 mg every 2 weeks for 12 weeks. During the remainder of the 52-week core study, patients given placebo were switched to izokibep 80 mg, and dosing intervals were adapted based on Psoriasis Area and Severity Index (PASI) scores for all patients. The core study was followed by two optional consecutive 1-year extension periods for a total duration of 3 years. The primary endpoint was a 90% reduction in PASI score (PASI 90) at week 12. Additional efficacy outcomes and adverse event (AE) rates were evaluated. Results In total, 109 patients were randomized [safety set, n = 108 (one exclusion criteria failure); full analysis set, n = 106]. At week 12, PASI 90 response rates were 0%, 5%, 19%, 71% and 59% for the placebo, 2-, 20-, 80- and 160-mg izokibep groups, respectively. Rapid dose-dependent improvements were also observed across other efficacy outcomes. During the placebo-controlled period, AEs in the izokibep groups were similar to placebo except for mild injection site reactions. AEs were generally mild to moderate and the drug was well tolerated. Izokibep maintained efficacy at the higher dosage groups for up to 3 years, with no new safety signals. Conclusions Data from this phase II study indicate that izokibep is well tolerated and efficacious in the treatment of plaque psoriasis. Higher doses or more frequent dosing could be explored to further enhance response rates. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Dermatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
